Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H5 AC-Anhui
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
H5 AC-Anhui is an **mRNA-based vaccine** encoding a hemagglutinin (HA) antigen derived from the A/Anhui/1/2005 (H5N1) influenza virus, specifically engineered to occupy an antigenically central position among A(H5) viruses. It aims to induce broad immune protection against divergent H5 highly pathogenic avian influenza viruses (HPAIVs). Preclinical studies have shown that H5 AC-Anhui provides non-inferior or improved protection compared to homologous vaccines in animal models, reducing infection severity and viral spread[1]. The vaccine is delivered as an **mRNA-lipid nanoparticle (LNP) formulation**. Its primary indication is for prophylactic vaccination against influenza A/H5 in healthy adults[3][5][7][9].
- Other names
- H5 AC-Anhui RNA VaccineH-5 AC-Anhui RNA VaccineH 5 AC-Anhui RNA VaccineAC-Anhui mRNA-LNP Vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on H5 AC-Anhui.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H5 AC-Anhui.